Amplitude’s intravascular lithotripsy technology could emerge as a challenger to Shockwave IVL, Leerink Partners analyst Mike ...
Amplitude Vascular’s lead development product is an intravascular lithotripsy platform for calcified peripheral artery disease treatment.
The funding round follows high-profile acquisitions by Boston Scientific and Stryker to pick up mechanical thrombectomy ...
Apex Securities Research has maintained an "overweight" rating on the Malaysian technology sector, highlighting a significant ...
E2 raises $80M to scale Hēlo®, improving pulmonary embolism treatment with faster, safer, and more efficient procedures.
Gilde Healthcare and Norwest co-led round to commercialize the Hēlo (R) Thrombectomy Platform ...
FDA-cleared in December 2025, E2’s Hēlo system is indicated for the non-surgical removal of emboli and thrombi from pulmonary ...
Okami Medical announced that it enrolled the first patient in the ALPHA Registry evaluating its LOBO vascular occlusion ...
California-based medtech E2 (Endovascular Engineering) has raised $80 million in a series C funding round as it looks to commercialize its pulmonary embolism treatment. | California-based medtech E2 ...
We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Rory Evans Rory Evans is a writer focused on skin-care and beauty products.